Secondary analysis of STEP TEENS (193 adolescents with obesity without type 2 diabetes): semaglutide 2.4 mg vs placebo gave greater 68-week reductions in fasting insulin (−33.6% vs −10.1%), HOMA-IR (−35.0% vs −5.3%), ALT, HbA1c and lipids.
Secondary analysisn = 193
Arslanian et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study